drugset / Trial / NCT03818542

A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT03818542

Phase 1 Terminated 3 enrolled AbbVie
Non-randomizedSequentialOpen-labelTreatment

Summary

A study evaluating the safety, pharmacokinetics, and biomarker profiles of multiple study drugs as monotherapy in subjects with newly diagnosed, treatment-naïve locally advanced squamous cell carcinoma of the head and neck who are candidates for surgical resection.

Timeline

Start
2020-01-22
Primary completion
2020-09-23
Completion
2020-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Budigalimab Monoclonal antibody Intravenous
Subject GILORALIMAB Monoclonal antibody Intravenous
Subject REVDOFILIMAB Monoclonal antibody Intravenous

Indications